nt has led to stroke progressing, we have been developed a new program for of a calculation of an individual dose by results of degree HCM + and weight of the patients. For decreased high coagulation potential it is necessary to begin prevention of thrombus formation with individual intramuscular using of new antiplatelet agent named acelysin (acetylsalicylate lysine). This therapy is necessary for applying once a day within 4-6 days. We estimated efficiency of new treatment at 89 patients (75,8% had high blood pressure or ischemic heart disease) with HCM + from I to X degree. In fig.1the concrete example of realisation of new strategy for prevention of an ischemic stroke at the patient with a hypertension and ischemic heart disease is presented.1 In hypertensive patient for prevention of stroke new technology Coaguloscope-TS (the patent of Ukraine) provides qualitative identification of a clinical (pathogenetic) risk factor of a vascular thrombosis and its degree (in 1 day CM +=VII degrees, for 30 day CM +=VIII degrees), and the use emerging therapy associated with treatment for rapidity (for 4-6 day) decrease of coagulation potential on 300-400% (CM +=2 degrees) after intramuscular therapy of an individual dose of the antiplatelet agent (an acelisin - once a day within 4-6 days), and including antihypertensive and lipid-lowering agents. the analysis of results it has been revealed, that after emergency treatment degree of a clinical risk factor has authentically decreased and level of CM + has changed from VII degree to 2,15 ± 0,25 degree (P lt; 0,0001), clot substances levels from 115,8 ± 4,72 mmol-eq/L to 84,51 ± 3,76 mmol-eq/L (P lt; 0,0001), clot substances density from 1775,19 ± 43,76 eq.units to 1525,92 ± 50,11 eq.units (P lt; 0,0001), and ratio between anticoagulation system level and procoagulant system level has increased from 81,57 ± 2,34 mmol-eq/L/min to 102,03 ± 3,75 mmol-eq/L/min (P lt; 0,0001). In patients with a high clinical risk factor (CM + VI-VIII degree) the coagulation potential often decreased to level of a low risk factor (CM + I-II degree). Thanks to high efficiency of treatment the clinical condition of patients improved, and signs of haemorrhage complications were absent.
Thus, the received results of investigation confirm, that the new program of diagnostics of an individual clinical (pathogenetic) risk factor developed by us, identification of various degrees of risk and new tactics of urgent treatment of a high risk factor have a more potential for the statement, that existing high rate of disability and death of the population from strokes and occurrence of bleeding episodes after antiplatelet therapy are connected with absence in recommendations of experts of the pathogenetic approach for primary and secondary prevention of this killer. Meanwhile in guidelines the 2012 Canadian Hypertension Education Program Recommendation for the Management of Hypertension ... (Canad. J. of Cardiol., 2012, 28: 270) are presented the evidence-based recommendation for the diagnosis, assessment, prevention, and treatment of hypertension without any laboratory tests for the investigation of coagulation and fibrinolysis state. On page 280 it is noticed, that strong consideration should be given to the addition of low-dose acetylsalicylic acid therapy and in high-risk patients, when combination therapy is being used, choices should be individualized. Unfortunately anybody from 64 authors have not presented the qualitative program of prevention of a stroke for health care practitioners.have represent recommendations which are based on results of investigation which have been published in journal of the Ukrainian Medical Association of North America, 1994, v. XLI, N 3 (94), p. 155-160; in materials of scientifically-practical conference «Modern aspects of military medicine», 1995, р. 287-289 (Kiev, Ukraine); in Ukrainian journal Medical News, 1996, N 9, p. 9-13; in Ukrainian journal Vrachebnoe Delo, 1997, N5, p. 56-59 (# justify gt; Vrachebnoe Delo, 2009, N 7-8, p. 32-40; 2010, N 5-6, p. 3-21.realization of individual primary and secondary stroke prevention program and reduce the impact of stroke on the lives of people and their families the first key component of this purpose is the urgent beginning of manufacture as stated above laboratory technology «Coaguloscope» (the patent of Ukraine).
